Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase iii study, prevent

HIGHLIGHTS

• who: Jürgen Braun from the Ruhr-University, Germany have published the paper: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT, in the Journal: (JOURNAL) of 02/03/2016
• what: The authors report the results of a post hoc analysis reporting the efficacy outcomes (pooled secukinumab) to 16 weeks by CRP MRI HLA-B27 and sex.
• how: Subgroup analyses based on CRP MRI HLA-B27 status and sex at screening are exploratory and only the percentage response or the mean change . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.